Phalguni Deswal

Alcon will license RxSight's light-adjustable technology in a non-exclusive deal worth up to $200m to co-develop tunable presbyopia-correcting IOLs, paying $60m upfront.

The eight-year post-acute care software venture is sold to Frazier Healthcare Partners at a notable discount from its 2018 acquisition price as the medtech leader pivots toward its 2030 growth strategy.

Roche and ABB are jointly developing AI-powered robotic systems for pathology and central laboratories, targeting workflow bottlenecks driven by labor shortages and precision medicine demand.

Medtech manufacturers, hospitals and EU trade bodies are pressing USTR to exempt medical devices from proposed Section 301 forced-labor tariffs, warning the levies would raise healthcare costs, disrupt fragile supply chains, and push production offshore rather than reshore it.

The FDA has designated Medtronic's recall of the Harmony Delivery Catheter System as Class I after reports the catheter's distal tip can detach during implantation. The action spares the Harmony pulmonary valve itself.

SpotitEarly CEO Shlomi Madar makes the case for breath-based cancer screening — trained beagles, sensors and AI reading VOCs — as GRAIL's NHS-Galleri miss reopens how MCED tests should be judged. He touts early-stage sensitivity, a de novo path and near-term PINK data.

J&J's immunology medical affairs leader Mark Graham talks to Scrip how the company is sequencing indications for the FcRn inhibitor Imaavy.

Abbott is investigating unauthorized access to a limited number of internal systems within its Cancer Diagnostics business, with no impact on operations or patient care. It is still determining what information was accessed and is separately probing a claimed intrusion into its LabCentral portal.

An AcuityMD-sponsored survey of 150 medtech reps finds AI users 3x likelier to hit quota — but only 36% use AI, and 11% for strategic work. Compliance, training gaps and generic tools stall adoption. The device-maker question, sources argue, is now how to deploy AI, not whether.

The FDA has named Dexcom the first participant in its TEMPO digital-health pilot, coordinating with CMS's outcomes-based ACCESS model in what amounts to the first federal attempt to run device market entry and reimbursement in parallel.